Ireland· IE-PA-EU/1/96/015/002
Epivir 10 mg/ml oral solution
A direct acting antivirals product containing lamivudine, registered in Ireland by ViiV Healthcare BV.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- Lamivudine
- Manufacturer
- ViiV Healthcare BV
- Country
- Ireland (IE)
- ATC code
- J05A
- ATC class
- DIRECT ACTING ANTIVIRALS
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/96/015/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lamivudine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesEPIVIRViiV Healthcare Company
- CzechiaEPIVIRViiV Healthcare BV, Amersfoort
- SpainEPIVIR 10 MG/ML SOLUCION ORALViiv Healthcare B.V.
- FinlandEpivirViiV Healthcare BV
- FranceEPIVIR 10 mg/ml, solution buvableVIIV HEALTHCARE UK (ROYAUME-UNI)
- BelgiumEpivir 10 mg/mlViiV Healthcare
- NetherlandsEpivir 10 mg/ml, drankViiV healthcare B.V.
- NorwayEpivirViiV Healthcare BV (1)
Authorised across Europe · EMA
The same active substance is authorised in 13 EEA countries. Names it is sold under:
- Austria · Lamivudin Sandoz
- Cyprus · Lamivudine Normon
- Germany · Lamivudin Aurobindo, Lamivudin Mylan
- Spain · Lamivudina Accord, Lamivudina Aurovitas
- France · Lamivudine Arrow, Lamivudine Sandoz
- United Kingdom (Northern Ireland) · Lamivudine Amarox, Lamivudine Generics
- Iceland · Epivir, Lamivudine Teva
- Italy · Lamivudina Aurobindo, Lamivudina Aurobindo Italia
- Liechtenstein · Epivir, Lamivudine Teva
- Netherlands · Lamivudine Accord, Lamivudine Aurobindo
- Norway · Epivir, Lamivudine Teva
- Poland · Lamivudine Aurovitas
- Portugal · Lamivudina Aurobindo, Lamivudina Farmoz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/040986e5-538a-4709-bc30-9c8e7876b7bd GET /v1/drugs/040986e5-538a-4709-bc30-9c8e7876b7bd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oral solution",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"J05A"
],
"strength": null,
"pa_number": "EU/1/96/015/002",
"substances": [
"Lamivudine"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "08/08/1996",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about lamivudine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.